Travere TherapeuticsvsUnitedHealth

TVTX and UNH stock compared: price, dividend, valuation and results, from SEC filings.

TVTX

Travere Therapeutics, Inc.

$48.30

Value $4.5B

-3.86%
TVTX's page

UNH

UnitedHealth Group Incorporated

$330.48

Value $300B

-5.55%
UNH's page

Travere Therapeutics (TVTX) has a market value of $4.5B and UnitedHealth (UNH) $300B. Over the last year, with dividends, TVTX moved +34.2% and UNH +8.2%. Dividend yield: TVTX none, UNH 2.74%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    TVTX$4.5B

    UNH$300B

    UNH is 67 times TVTX

  • Revenue, 12 months

    TVTX$651M

    UNH$450B

    UNH is 691 times TVTX

  • Net income, 12 months

    TVTX-$122M

    UNH$15.9B

  • Operating margin

    TVTX-20.5%

    UNH5.3%

    25.8 points apart

  • ROIC

    TVTX-25.2%

    UNH11.3%

    36.5 points apart

  • P/E

    TVTX–

    UNH18.9

  • Dividend yield

    TVTX0.0%

    UNH2.7%

    2.7 points apart

  • 5-year return

    TVTX+64.7%

    UNH-19.5%

    84.2 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

TVTX+64.7%

UNH-19.5%

10020020222023202420252026
Returns by period
PeriodTVTXWith dividendsUNHWith dividends
1 year since November 18, 2025+34.2%Price +34.2%+8.2%Price +5.4%
3 years since November 17, 2023+725.6%+102.1% a yearPrice +725.6%-34.4%-13.1% a yearPrice -38.4%
5 years since November 18, 2021+64.7%+10.5% a yearPrice +64.7%-19.5%-4.2% a yearPrice -26.5%
10 years since November 21, 2016+127.6%+8.6% a yearPrice +127.6%+159.4%+10.0% a yearPrice +119.7%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

TVTXTravere TherapeuticsUNHUnitedHealth

Valuation

TVTXUNH
Valuation
Price$48.30$330.48
Market value$4.5B$300B
Enterprise value (EV)$4.5B$346B
P/E–18.9
P/E, 5-year median–25.0
P/B197.32.9
EV/EBIT–14.5
Free cash flow yield–7.6%

Results and growth

TVTXUNH
Results and growth
Revenue, 12 months$651M$450B
Net income, 12 months-$122M$15.9B
Free cash flow, 12 months–$22.8B
Earnings per share, 12 months-$1.29$17.52
Revenue growth, year on year110.5%11.8%
Revenue growth a year, past+19.9%over 5 years+11.7%over 5 years
EPS growth a year, past–-3.8%over 5 years

Margins and returns on capital

TVTXUNH
Margins and returns on capital
Gross margin98.5%88.3%
Operating margin-20.5%5.3%
Net margin-18.7%3.5%
ROIC-25.2%11.3%
ROE-181.8%15.5%

Balance sheet

TVTXUNH
Balance sheet
Cash$303M$28.5B
Total debt$324M$74.3B
Net debt / EBITDA–1.6
Interest cover-15.1×6.2×

Dividends and buybacks

TVTXUNH
Dividends and buybacks
Dividend yield–2.7%
Dividend per share, 12 months–$9.06
Dividend growth a year, past–+12.6%over 5 years
Buyback yield–1.8%
Shareholder yield–4.6%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: TVTX or UNH

Didn't find what you were looking for?

Ask us
Which is bigger, Travere Therapeutics or UnitedHealth?

By market value, UnitedHealth ($300B) is about 67.3 times Travere Therapeutics ($4.5B), at today's prices.

How did TVTX and UNH stock do over the last 10 years?

Since November 21, 2016, TVTX's price moved +127.6% and UNH's +119.7%. With dividends: TVTX +127.6% (+8.6% a year), UNH +159.4% (+10.0% a year). Past returns do not predict future ones.

Which pays the higher dividend, TVTX or UNH?

The dividend yield at today's price is none for Travere Therapeutics and 2.74% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.

Which has the higher profit margins, Travere Therapeutics or UnitedHealth?

Over the last twelve months, the net margin was -18.7% for Travere Therapeutics and 3.5% for UnitedHealth, and the operating margin -20.5% and 5.3%. Revenue was $651M and $450B.

Which is the better investment, Travere Therapeutics or UnitedHealth?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.